SUNRAY-02: what clinicians are saying
olomorasib plus pembrolizumab; olomorasib plus durvalumab in stage II-III KRAS G12C-mutant non-small cell lung cancer · NCT06890598 ↗ · Phase 3 · Eli Lilly and Company
A speaker whose identity and clinical role are not established expresses interest in SUNRAY-02’s treatment timing, without assessing benefit. More detailed commentary concerns LOXO-RAS-20001 and a chemotherapy-containing regimen a medical oncologist judged tolerable and attributed to this trial, although it differs from the protocol. Their broader treatment-selection concerns center on toxicity. The sources reviewed for this edition do not establish trial-specific benefit or safety.
Created with AI · how we check it
- edition 1
- commentary checked Nov 22, 2026
- 42 verified statements
This edition $750, with MCP access for your AI agent. Get this report
4 findings, and what sits behind each
01. SUNRAY-02: what speakers say
1 of the report's 3 cited clinicians · 4 statements from 1 speaker in 3 sources · 5 passages
Limitations recorded: 2.
Draws on: The comparison, Population and setting, Design and conduct.
Beyond the trial population
02. Olomorasib with chemotherapy: a clinician weighs preliminary safety, noting cytopenias
1 of the report's 3 cited clinicians · 5 statements from 1 speaker in 2 sources, 1 of them a podcast or video · 3 passages
Limitations recorded: 3.
03. LOXO-RAS-20001: what speakers highlight in first-line PD-L1-high responses
1 of the report's 3 cited clinicians · 9 statements from 2 speakers in 5 sources · 5 passages
Limitations recorded: 3.
04. Combinations: how a clinician weighs toxicity and single-agent options
1 of the report's 3 cited clinicians · 2 statements from 1 speaker in 1 source, a podcast or video · 2 passages
Limitations recorded: 2.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 4
1 of the report's 3 cited clinicians
SUNRAY-02: what speakers say
4 statements from 1 speaker in 3 sources
- 4
- statements
- 5
- passages
- 3
- sources
- 1
- speaker
What the statements areViews 1Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 3Statement-to-passage links (a passage can back several statements)Supporting a statement 5Giving context 0Recorded with the findingLimitations: 2
2 posts and articles · 1 publication
Draws on: The comparison, Population and setting, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
3 of the 4 findings and 15 of the 42 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (7)
BICR, blinded independent central review; DFS, disease-free survival; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; PD-L1, programmed death-ligand 1; PFS, progression-free survival.
The full SUNRAY-02 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 29commentary sources screened
- 8sources cited by verified statements
- 4named in screened sources
- 4speakers cited in the report
- 3cited speakers with a verified identity
3 cited clinicians, speakers with a confirmed clinical role, of them 3 physicians. By role and specialty:
- 2 physician, Medical oncology
- 1 physician, specialty not confirmed
Also in the sources: 1 organizational or shared account, not counted as people.
- 42verified statements, each linked to its source
- 12of them from speakers with a confirmed clinical role
- 4findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 42 | Paid |
| Who said each statement: the cited speakers | 4 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 3 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 10 | Free |
| Sources with links | 8 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
7 discussed · 3 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Part A: Disease-Free Survival (DFS) by Investigator Assessmentno commentary found | 0 | 0 |
| Primary endpoint: Part B: Progression-Free Survival (PFS) by BICRno commentary found | 0 | 0 |
| Secondary endpointsno commentary found | 0 | 0 |
| Population and setting | 1 | 1 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 2 | 2 |
| Safety and tolerability | 4 | 3 |
| Design and conduct | 1 | 1 |
| Earlier-phase efficacy and biomarker rationale | 6 | 4 |
| Regimen naming and cross-study interpretation | 4 | 1 |
| Individualized combination versus single-agent selection | 2 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
42 verified statements from 8 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 6 statements · 14% | ||||
| YouTube | 6 | 1 | 1 | |
| Posts · 10 statements · 24% | ||||
| X threads | 6.5 | 4 | 25 | |
| LinkedIn posts | 3.5 | 2 | 2 | |
| Bluesky threads | 0 | 0 | 1 | |
| Primary sources · 26 statements · 62%cited for context, not screened | ||||
| Publications | 26 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 6 / quarter
- Screened window
- Apr 16, 2025 → Nov 20, 2026
- Cited window
- Apr 16, 2025 → Nov 20, 2026
- Retrieved
- Nov 21, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
- Registry
- NCT06890598
- Study IDs
- 18763 · 2024-512302-25-00 · J3M-MC-JZQH (Eli Lilly and Company)
- Sponsor
- Eli Lilly and Company
- Collaborators
- AstraZeneca
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 700 estimated
- Registered
- 2025-03-24
- Start
- 2025-03-27 actual
- Primary completion
- 2029-05 estimated
- Primary endpoints
- Part A: Disease-Free Survival (DFS) by Investigator Assessment
- Part B: Progression-Free Survival (PFS) by BICR
- Interventions
- 4 registered
More on: Non-small cell lung cancer, olomorasib, pembrolizumab, durvalumab
Discussed at: European Lung Cancer Congress 2026, IASLC 2026 World Conference on Lung Cancer
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 24 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 29 sources about other trials or topics are not included.
- The cited commentary does not report SUNRAY-02 efficacy or safety outcomes. Its response and toxicity figures concern LOXO-RAS-20001 or other described combinations, and the linked SUNRAY-02 publication describes methods and rationale.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
Show all 7 known gaps +Fewer −
- A speaker’s LinkedIn and X posts repeat the same view. Publication and posting dates do not establish presentation dates, readout timing or changes of opinion.
- ClinicalTrials.gov did not list a separate protocol document in the sources reviewed; methods context comes from the protocol publication. No exact olomorasib regulatory label was identified, so this report does not assess labeling or regulatory status.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 22, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. SUNRAY-02 (NCT06890598): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/sunray-02-nct06890598
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "SUNRAY-02" (NCT06890598), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "sunray-02-nct06890598". If you cannot make requests, read https://www.erudio.com/reports/sunray-02-nct06890598.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06890598", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06890598 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/sunray-02-nct06890598.json
curl https://www.erudio.com/reports/sunray-02-nct06890598.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "sunray-02-nct06890598" })release 6b191e5d20cfea3f3ee70c88858755234cd4039d2df4fd71817e1bb7b4c85593
Questions
How much does the SUNRAY-02 report cost?
One edition costs $750 (Focused · 42 verified statements · 12 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the SUNRAY-02 report cover?
42 statements from 8 sources (1 video, 6 posts, 1 paper), 12 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the SUNRAY-02 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "sunray-02-nct06890598" }) previews it and create_order({ "report": "sunray-02-nct06890598", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the SUNRAY-02 report?
Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.